---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-26-000025"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T08:58:56.399630+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway

## Summary
- Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.
- Cash, equivalents and short-term investments of $17.1M as of Dec 31, 2025; expects runway into late 2027.
- KIO-301 Phase 2 ABACUS-2 trial for retinitis pigmentosa advancing; initial data readout expected Q3 2027.
- KIO-104 Phase 2 KLARITY trial for macular edema dosing; non-cash impairment charge in Q4.
- Executed option agreement with Senju for KIO-301 in Asia with potential value up to $110M plus royalties.

## SEC filing metadata
- accession: 0001372514-26-000025
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000025/0001372514-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251426000025/kprx-20260325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-26-000025
- JSON: https://secwatch.observer/filing/0001372514-26-000025.json
- Plain text: https://secwatch.observer/filing/0001372514-26-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.